BB-norm+ner@ldeleger:BB-norm+ner-23704121 / 310-603
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/BB-norm+ner@ldeleger/sourceid/BB-norm+ner-23704121","sourcedb":"BB-norm+ner@ldeleger","sourceid":"BB-norm+ner-23704121","text":"We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results.","tracks":[{"project":"bionlp-ost-19-BB-norm-ner-train","denotations":[{"id":"T3","span":{"begin":0,"end":293},"obj":"Paragraph"}],"attributes":[{"subj":"T3","pred":"source","obj":"bionlp-ost-19-BB-norm-ner-train"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"bionlp-ost-19-BB-norm-ner-train","color":"#93beec","default":true}]}]}}